

RETRACTED

[View retraction](#)

Amendment history:

- [Retraction](#) (February 2026)

***Lkb1* deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation**

Yujiao Han, Heng Feng, Jun Sun, Xiaoting Liang, Zhuo Wang, Wenhui Xing, Qinggang Dai, Yang Yang, Anjia Han, Zhanying Wei, Qing Bi, Hongbin Ji, Tiebang Kang, Weiguo Zou


J Clin Invest. 2019;129(5):1895-1909. <https://doi.org/10.1172/JCI124590>.

Research Article

Bone biology

Oncology

Graphical abstract



Find the latest version:

<https://jci.me/124590/pdf>



Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation

Yujiao Han,¹ Heng Feng,¹ Jun Sun,¹ Xiaoting Liang,² Zhuo Wang,³ Wenhui Xing,¹ Qinggang Dai,⁴ Yang Yang,¹ Anjia Han,³ Zhanying Wei,⁵ Qing Bi,⁶ Hongbin Ji,^{1,7} Tiebang Kang,² and Weiguo Zou¹

¹State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Sciences, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Shanghai, China. ²State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. ³Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. ⁴The Second Dental Center, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ⁵Department of Osteoporosis and Bone Diseases, Metabolic Bone Disease and Genetics Research Unit, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. ⁶Zhejiang Provincial People's Hospital, Hangzhou, China. ⁷School of Life Science and Technology, Shanghai Tech University, Shanghai, China.

Bone osteogenic sarcoma has a poor prognosis, as the exact cell of origin and the signaling pathways underlying tumor formation remain undefined. Here, we report an osteogenic tumor mouse model based on the conditional knockout of liver kinase b1 (*Lkb1*, also known as *Stk11*) in *Cathepsin K-Cre*-expressing (*Ctsk-Cre*-expressing) cells. Lineage-tracing studies demonstrated that *Ctsk-Cre* could label a population of periosteal cells. The cells functioned as mesenchymal progenitors with regard to markers and functional properties. LKB1 deficiency increased proliferation and osteoblast differentiation of *Ctsk*⁺ periosteal cells, while downregulation of mTORC1 activity, using a *Raptor* genetic mouse model or mTORC1 inhibitor treatment, ameliorated tumor progression of *Ctsk-Cre Lkb1*^{fl/fl} mice. Xenograft mouse models using human osteosarcoma cell lines also demonstrated that LKB1 deficiency promoted tumor formation, while mTOR inhibition suppressed xenograft tumor growth. In summary, we identified periosteum-derived *Ctsk-Cre*-expressing cells as a cell of origin for osteogenic tumor and suggested the LKB1/mTORC1 pathway as a promising target for treatment of osteogenic tumor.

Introduction

Osteogenic tumor is the most common primary tumor of the bone tissue, including benign bone-forming neoplasm, osteoma, osteoblastoma, and a malignant neoplasm called osteogenic sarcoma, also referred to as osteosarcoma (1). The hallmark diagnostic feature of osteogenic tumor is the detection of mineralized bone or osteoid matrix produced by the neoplastic cells, with a very broad spectrum of histological appearances (2). Osteogenic sarcoma arises primarily in children and adolescents, with a second incidence peak in aged people. It confers a poor prognosis, as the survival benefit of traditional chemotherapy treatment remains unsatisfactory. More targeted and personalized therapies for osteogenic sarcoma treatment are urgently required (1). A growing body of evidence indicates that mouse models can recapitulate the fundamental aspects of human osteogenic sarcoma and offer the ability to yield therapeutic targets that will eventually allow customized cancer treatment (3). Furthermore, modeling human cancers using transgenic mice or knockout mice has been proven to further our understanding of the exact cell of origin and the signaling pathways underlying tumor formation (4).

Mutations in *p53* and/or *Rb* genes, as well as other components involved in their pathways, have been identified in human osteogenic sarcoma patients, and mouse models for studying the cell of origin for osteogenic sarcoma have been developed via conditional mesenchymal/osteogenic lineage-restricted knockout of *p53* and/or *Rb* genes (5–9). The disruption of *p53/Rb* in mesenchymal progenitors (*Prx1-cre*), osteoblast precursors (*Osx-Cre*), and osteoblast committed cells (*Col1a1-Cre* and *OCN-Cre*) leading to osteogenic sarcoma confirmed that cells with mesenchymal origin and osteogenic lineage were responsible for osteogenic tumor formation (4, 10–12). Moreover, NOTCH activation in committed osteoblasts (*Col1a1-Cre*) was sufficient to induce osteogenic sarcoma, also suggesting committed osteoblasts as the potential sources of osteogenic tumor (13). However, the exact cell of origin with distinct genetic mutations that is responsible for the individual subtypes remains to be described (14, 15).

Liver kinase b1 (LKB1, also known as *Stk11*), is a master serine/threonine kinase that links energy homeostasis and cell growth through the mTORC1 pathway (16). Loss of *Lkb1* in a variety of organs has been reported to initiate both hyperplasia and tumorigenesis (17). Cancers with *Lkb1* inactivation tend to exhibit aggressive clinical characteristics, and their therapeutic sensitivity differs from those without *Lkb1* inactivation (18–21). Previous studies indicated that *Lkb1* may also be involved in bone cancer. *Lkb1* heterozygous germline mutant (*Lkb1*^{+/-}) mice develop gastrointestinal polyps and multifocal osteogenic tumors (22, 23). A recent study showed that 41% of osteosarcoma patients lost LKB1 protein expression and that most of them showed mTORC1 activation

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2019 Han et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: August 31, 2018; **Accepted:** February 13, 2019; **Published:** March 25, 2019.

Reference information: J Clin Invest. 2019;129(5):1895–1909.

<https://doi.org/10.1172/JCI124590>.

(24). Although the loss of *Lkb1* has been suggested as correlating with osteogenic tumor, the involved cell type and the underlying pathway remain unclear; however, these details are central for a complete understanding of osteogenic tumor formation.

Cathepsin K (CTSK) is a cysteine protease secreted by osteoclasts and is essential for the degradation of matrix collagen during bone resorption (25). The *Ctsk* promoter has been suggested as being active in osteoclasts only (26), and *Ctsk-Cre* mice have been widely used to study osteoclast function (27). A recent study demonstrated that *Ctsk-Cre*-expressing cells can be chondroprogenitor cells, as *Ptpn11* deletion in *Ctsk-Cre*-expressing cells resulted in metachondromatosis by activating Hedgehog signaling (28). Lack of *Lkb1* within chondrocytes (*Col2a1-Cre*) of the endochondral skeleton caused a dramatic disruption of the skeletal growth plate and formation of cartilage tumors (29). This suggests that *Lkb1* deletion in *Ctsk-Cre*-expressing cells causes cartilage tumors. Interestingly, in this study, we found that deletion of *Lkb1* in *Ctsk-Cre*-expressing cells caused an osteogenic tumor-like phenotype, but not cartilage tumors. The features included an overall disruption of cortical bones as well as increased osteoid formation and bone turnover. Lineage tracing indicated that *Ctsk-Cre* could label a population of periosteum-derived cells, which could function as mesenchymal progenitors in terms of markers and functional properties.

In this study, we identified a cell of origin for osteogenic tumor and suggested *Lkb1* as a tumor suppressor in the primary bone tumor, thus advancing our knowledge of both the cell of origin and the molecular genetics of osteogenic tumor. Furthermore, our data supported that *Ctsk-Cre*-expressing cells could serve as progenitors of both cartilage tumor and osteogenic tumor under the regulatory effects of different signaling. Moreover, these results indicated the therapeutic potential of mTORC1 inhibitors for the treatment of osteogenic sarcoma.

Results

***Lkb1* deficiency in *Ctsk-Cre*-expressing cells causes osteogenic tumor-like phenotype.** To investigate the role of *Lkb1* in *Ctsk-Cre*-expressing cells, we generated *Ctsk-Cre; Lkb1^{fl/fl}* mice (hereafter named Ctsk-CKO). Lack of *Lkb1* within chondrocytes (*Col2a1-Cre*) of the endochondral skeleton caused cartilage tumors (29), and *Ctsk-Cre*-expressing cells were identified as the source of metachondroma (28); therefore, *Lkb1* loss in Ctsk⁺ cells was supposed to lead to cartilage tumors. Strikingly, Ctsk-CKO mice did not display cartilage tumors, as indicated by H&E staining and safranin O (SO) staining in both the femurs and tibiae and the sternums (Supplemental Figure 1, A and B; supplemental material available online with this article; <https://doi.org/10.1172/JCI124590DS1>), but these mice exhibited a specific skeleton phenotype (Supplemental Figure 2A). However, neither *Lkb1^{fl/fl}* nor *Ctsk-Cre; Lkb1^{fl/+}* mice showed a discernible phenotype (Supplemental Figure 2A). Therefore, *Ctsk-Cre; Lkb1^{fl/+}* mice (hereafter named Ctsk-Ctrl) were used as controls in the following study.

Ctsk-CKO mice displayed overgrowth before the age of 13 weeks and began to lose weight from the age of 13 weeks (Figure 1A), and 85% died before the age of 30 weeks (Figure 1B). Radiographic examination showed that 100% of Ctsk-CKO mice displayed progressively thicker bones at sites of the femur, tibia, vertebrae, sternum, cranium, and mandible from the age of 20 weeks

and that this phenotype aggravated with age (Figure 1, C and D, and Supplemental Figure 2B). μ CT analysis showed disorganized bone architecture and the presence of ossified spicules outside the periosteum in both axial and appendicular skeletons of Ctsk-CKO mice (Figure 1, C and D). H&E staining of tibiae from Ctsk-CKO mice showed progressive histopathological features of osteogenic tumor: expansive osteoid lesions with mushroom-shaped appearance located in the cortical bone and beginning of invasion of the medullary cavity from the age of 20 weeks (Figure 1E). The tumor gradually formed a large mass, transgressing the cortex and invading into adjacent muscle and fat tissues at the age of 40 weeks (Figure 1, E and F, and Supplemental Figure 2C), mimicking malignant human osteogenic sarcoma. Nuclear atypia of cells that compose the osteoid matrix gradually increased from mild to severe with age (Figure 1E). The tumor presented a high proliferation rate, measured via elevated cell proliferation marker Ki67 (Figure 1G).

As lack of *Lkb1* in Ctsk⁺ cells led to a tumor-like mass in the cortical bone, the expression levels of genes involved in the cell cycle, including *Ccnd1*, *Cdkn1a*, *Cdkn2a*, and *Cdkn2b*, were determined to characterize the tumor and it was found that they were significantly increased in Ctsk-CKO tibiae at the age of 20 weeks (Figure 1H). We furthermore observed increased expression of the osteogenic sarcoma oncogene *Mdm2* and Notch target gene *Hey1* in Ctsk-CKO mice, which were frequently upregulated in osteosarcoma patients or mouse models (13, 30). The expression levels of the tumor suppressors *Rb* and *Bub3* were decreased in Ctsk-CKO mice as expected, while decreased expression levels of the tumor suppressor genes *p53*, *Wif*, and *Fgfr2* were not detected in Ctsk-CKO mice (8, 11, 31, 32) (Figure 1H). We also examined expression of these genes between control and mutant mice before the tumor mass appeared at the age of 5 weeks and found that expression levels of cell cycle-related genes showed more moderate changes (Supplemental Figure 2D). Interestingly, we found an obvious elevated expression of *Fgfr2* at the age of 5 weeks (Supplemental Figure 2D), which was highly involved in cell fate, cell proliferation, and tumor induction, prompting us to trace the phenotype and gene expression of Ctsk-CKO mice before tumor formation.

***Lkb1* deletion in *Ctsk-Cre*-expressing cells results in enhanced bone formation in mice.** To examine bone architecture of Ctsk-CKO mice before tumor formation, we did a quantitative μ CT analysis and found an increase in the cortical bone thickness and heterotopic bone formation within the cortex in Ctsk-CKO mice (Figure 2, A and B). However, the percentage of bone volume per tissue volume (BV/TV) within the cortical bone of Ctsk-CKO mice was decreased (Figure 2, A and B). von Kossa staining confirmed the mineralization of the heterotopic bone within the cortex (Figure 2C). The thickened diaphyseal cortex then prompted us to test the bone formation rate (BFR) in Ctsk-CKO mice. To determine the BFR, dynamic histomorphometry analysis was performed by double labeling with calcein and alizarin red, which are markers of newly formed bone. Compared with Ctsk-Ctrl mice, Ctsk-CKO mice displayed more heterotopic newly synthesized osteoid in the cortical bones (Figure 2D). The mineral apposition rate (MAR) and BFR at the periosteal surface of the tibiae of 5-week-old Ctsk-CKO mice were significantly increased compared with those of Ctsk-Ctrl mice (Figure 2, D and E). Moreover, higher mRNA levels of marker genes, representing stages of osteoblast differentiation




Figure 1. *Lkb1* deletion in *Ctsk-Cre*-expressing cells causes osteogenic tumor-like phenotype. (A) Body weight plots of Ctsk-Ctrl ($n = 10$) and Ctsk-CKO ($n = 8$) male mice. (B) Kaplan-Meier survival plots of Ctsk-Ctrl ($n = 31$) and Ctsk-CKO ($n = 21$) mice. (C and D) X-ray images and μ CT scans of the spines (C) and tibiae (D) of 20-week-old Ctsk-Ctrl and Ctsk-CKO mice. (E) H&E staining of tibiae from 4-, 20-, 30-, and 40-week-old Ctsk-CKO mice showed a progressive histopathological feature. Scale bar: 1 mm (upper panels); 20 μ m (lower panels). (F) Tumor in the tibiae of Ctsk-CKO mice was composed of fibroblastic and osteoblastic cells with abundant blood vessels. It invaded into the adjacent muscle and fat tissues at an age of 40 week. Scale bars: 50 μ m. (G) Immunostaining of Ki67 in the tumor osteoid displayed a hyperproliferative characteristic. Scale bar: 50 μ m. Similar results were obtained from analyses of both male and female mice for each genotype. (H) Gene expression of human osteosarcoma-related genes in the cortical bone of tibiae from 20-week-old female Ctsk-CKO mice ($n = 3$) compared with normal Ctsk-Ctrl mice ($n = 4$). Data are represented as mean \pm SEM. $*P < 0.05$; $**P < 0.01$; $***P < 0.001$, unpaired Student's *t* test.

(9), were detected in tumors of 20-week-old Ctsk-CKO mice compared with the cortical bone of tibiae from Ctsk-Ctrl mice (Figure 2F). The osteoblast markers were also examined at the age of 2 weeks. The results showed that preosteoblast markers *Alp* and *Col1a1* were specifically increased, indicating activation of bone formation in Ctsk-CKO mice (Supplemental Figure 2E). In accordance with observed increased osteoblast activity, the tumor was largely composed of osteoblastic cells, as indicated by immuno-

staining of the osteoblastic markers osterix (OSX) (Figure 2G) and osteopontin (OPN) (Figure 2H).

Lkb1 deficiency in osteoclast precursors does not induce osteogenic tumor-like phenotype. *Ctsk-Cre* mice have been widely used to study osteoclast function due to the abundant and selective expression of *Ctsk* in osteoclasts (27). We next assessed whether this increased bone mass in Ctsk-CKO mice was the result of impaired osteoclast activity. We used tartrate-resistant




Figure 2. *Lkb1* deletion in *Ctsk-Cre*-expressing cells leads to increased bone formation. (A) μ CT analysis of femurs from 5-week-old female Ctsk-Ctrl and Ctsk-CKO mice. (B) Ct.Th and BV/TV of the cortical bones of femurs from 5-week-old female Ctsk-Ctrl and Ctsk-CKO mice ($n = 5$ for each group). (C) von Kossa staining of the tibiae from 5-week-old female Ctsk-Ctrl and Ctsk-CKO mice. Scale bar: 100 μm . (D and E) Calcein-alizarin red double-labeled fluorescence of the tibiae from 5-week-old female Ctsk-Ctrl and Ctsk-CKO mice showing MAR and BFR of the periosteum ($n = 3$ for each group). Scale bars: 100 μm (left); 10 μm (right). (F) Gene expression of markers for osteoblast progenitor (*Runx2* and *Osx*), preosteoblast (*Alp* and *Col1a1*), and mature osteoblast (*Opn*, *Bsp*, and *Ocn*) of the cortical bones of 20-week-old female Ctsk-CKO mice ($n = 3$) compared with Ctsk-Ctrl mice ($n = 4$) tibiae. (G and H) Immunostaining of OSX (G) and OPN (H) in the tumor osteoid of Ctsk-CKO tibiae. Scale bars: 50 μm . Data are represented as mean \pm SEM. * $P < 0.05$; ** $P < 0.01$, unpaired Student's *t* test.

acid phosphatase (TRAP) staining and found that osteoclast numbers in the periosteum, endosteum, and trabecular bone were increased in Ctsk-CKO mice when compared with the control mice (Figure 3A). We also cultured bone marrow (BM) cells from Ctsk-Ctrl and Ctsk-CKO mice; then the cells were differentiated into osteoclasts in the presence of monocyte/macrophage CSF (M-CSF) and RANKL. Quantification of TRAP activity demonstrated an increased osteoclast formation ability in Ctsk-CKO BM cells (Figure 3, B and C). These data indicate that the increased bone mass of Ctsk-CKO mice was not due to impaired resorption ability. To further rule out that the increased bone mass of Ctsk-CKO mice originated from the extrinsic role of *Lkb1*-deficient osteoclasts, we generated *LysM-Cre; Lkb1^{fl/fl}* mice in which the *LysM* promoter was active in monocytes, macrophages, and osteoclast precursors (33). *LysM-CKO* mice did not show a discernible osteogenic tumor-like phenotype at the age of 20 weeks (Figure 3, D–F) and 40 weeks (data not shown), indicating that the osteogenic tumor-like phenotype in Ctsk-CKO mice was not the result of altered osteoclast function.

Ctsk-Cre-expressing periosteal mesenchymal cells are potential sources for osteogenic tumors. In response to the results presented so far, we hypothesized that a *Ctsk-Cre*-positive but *LysM-Cre*-negative mesenchymal cell population might cause osteogenic tumor in Ctsk-CKO mice. To identify this cell population, we performed lineage-tracing studies using *Rosa 26-mT/mG* mice, which constitutively express membrane-targeted Tomato fluorescent protein and membrane-targeted GFP upon Cre-mediated recombination (34) (Figure 4A). As expected, a *Ctsk-Cre*-positive but *LysM-Cre*-negative population was found in the periosteum of cortical bone (Figure 4B), although both *Ctsk-Cre* and *LysM-Cre* were expressed in osteoclasts on the surface of trabecular bone at the age of 4 weeks (Supplemental Figure 3A). More importantly, *Ctsk-Cre*-positive cells expanded and filled within the cortical bone of tibiae from Ctsk-CKO mice with age growth (Supplemental Figure 3B). The osteoid tumor area in Ctsk-CKO tibiae was mainly formed by GFP-positive cells by the age of 20 week (Figure 4C and Supplemental Figure 3B), indicating that the osteogenic tumor in Ctsk-CKO mice was caused by intrinsic




Figure 3. Loss of *Lkb1* in osteoclast precursors does not cause osteogenic tumor-like phenotype. (A) TRAP staining of trabecular bone, periosteum (po), and endosteum (endo) of tibiae from 5-week-old Ctsk-Ctrl and Ctsk-CKO mice. Scale bar: 100 μ m. (B and C) TRAP staining (B) and quantification of TRAP activity (C) of cells differentiated from Ctsk-Ctrl and Ctsk-CKO BM cells in the presence of M-CSF and RANKL. (D–F) Phenotypic analysis of 20-week-old LysM-Ctrl and LysM-CKO mice did not show osteogenic tumor formation. Representative x-ray images (D) and μ CT (E) scans of the spines and tibiae and H&E staining of the tibiae (F) of 20-week-old LysM-Ctrl and LysM-CKO mice. Scale bars: 300 μ m. Similar results were obtained from analyses of both male and female mice for each genotype. Data are represented as mean \pm SEM. * P < 0.05; ** P < 0.01, unpaired Student's t test.

Lkb1 deletion in *Ctsk-Cre*-expressing cells. To further determine the role of Ctsk⁺ cells in tumor formation, another mouse reporter strain (*Rosa26-Ai9*) was used, which conditionally expresses fluorescent protein tdTomato in response to Cre recombinase activation (35) (Figure 4D). The *Rosa26-Ai9* reporter mice showed bright single fluorescence that greatly facilitated in vivo imaging. Expansion of *Ctsk-Cre*-expressing cells was also observed in the cortical bone of *Ctsk-CKO*; *Rosa-Ai9* tibiae at the age of 4 weeks (Figure 4E). We further examined cell identity of Ctsk⁺ cells through FACS analyses. Three populations, including CD200⁺CD105⁺, previously described as skeletal stem cell (SSC), CD200⁺CD105⁺ pre-bone-cartilage-stromal progenitor (pre-BCSP), and CD105⁺BCSP (36) were identified from CD31⁺, CD45⁺, TER119⁺ (Lin⁺) CD90.2⁺CD3⁺ Ctsk-Ai9⁺ cells (Figure 4F and Supplemental Figure 4B), which is consistent with the recent study showing that *Ctsk-Cre* labels periosteal mesenchymal cells (37). Furthermore, we also analyzed the expression of common stem cell markers in Ctsk⁺ cells and found expression of Sca1, CD24, CD44, CD49f, and CD146 in Ctsk⁺ cells (Supplemental Figure 4C). We next investigated the differentiation potential of periosteal Ctsk⁺ cells and found that they are capable of differentiating into osteoblast,

chondrocyte, and adipocyte in vitro, as demonstrated by alkaline phosphatase (ALP), Alcian blue, and oil red O staining and expression of corresponding differentiation markers (Supplemental Figure 4A), further demonstrating the Ctsk can label a population of mesenchymal stem cells.

We then examined LKB1 expression in the periosteum of Ctsk-positive cells via immunofluorescence. The results confirmed deletion of LKB1 expression in Ctsk⁺ periosteal cells from *Ctsk-CKO*; *Rosa-Ai9* mice, but not in *Ctsk-Ai9* cells from *Ctsk-Ctrl*; *Rosa-Ai9* mice (Figure 4, G and H). Interestingly, we found that not all the Ctsk⁺ cells expressed LKB1 (Figure 4, G and H). FACS analysis further confirmed the percentage of Ctsk⁺LKB1⁺ cells in Ctsk⁺ periosteal cells. Interestingly, we found a higher percentage of Lin⁺CD90.2⁺CD105⁺CD200⁺ cells in the Ctsk⁺Lkb1⁺ population when compared with Ctsk⁺Lkb1[−] cells (Supplemental Figure 4D), indicating the expression of LKB1 within Ctsk⁺ stem cells and tumorigenesis might occur specifically within this stem cell population.

Next, we asked whether periosteal Ctsk-Ai9 cells have osteogenic tumor initiation potential in Ctsk-CKO mice. We found increased expression levels of osteoblast markers, including OSX, COL1A1, and OPN, in periosteal mesenchymal Ctsk-Ai9 cells of




Figure 4. *Ctsk-Cre*-expressing periosteal mesenchymal stem cells are potential sources for osteogenic tumor. (A) Schematic of experiments on *Rosa26-loxp-mTomato-stop-loxp-GFP* (*Rosa26-mT/mG*) Cre reporter mice. (B) Confocal images of the tibiae of 4-week-old male *LysM-Cre; Rosa26-mT/mG* and *Ctsk-Cre; Rosa26-mT/mG* reporter mice showing that *Ctsk-Cre; GFP* (green), but not *LysM-Cre; GFP* (green) was expressed in the periosteum of cortical bone (indicated with the white arrow). Right panel: in *Ctsk-CKO* mice, *Ctsk*-positive cells at the periosteum expanded within the cortical bone. Scale bar: 50 μ m. (C) Confocal images showing that the majority of the cells in the tumor region of 20-week-old male *Ctsk-CKO; Rosa26-mT/mG* mice are *Ctsk-Cre; GFP*-expressing cells (green). Scale bars: 300 μ m (left); 50 μ m (right). (D) Schematic of experiments on *Rosa26-loxp-stop-loxp-tdTomato* (*Rosa26-Ai9*) Cre reporter mice. (E) Images of 4-week-old male *Ctsk-Ctrl; Rosa26-Ai9* and *Ctsk-CKO; Rosa26-Ai9* tibiae showing expansion of *Ctsk-Cre*-expressing cells (red) in *Ctsk-CKO* mice. Scale bars: 300 μ m (left); 20 μ m (right). (F) Flow cytometry of cells from periosteum of 4-week-old male *Ctsk-Ctrl; Rosa26-Ai9* mice to identify expression of SSC markers CD105 and CD200 in Lin-CD90.2-6C3-*Ctsk-Ai9*⁺ cells. (G and H) Immunostaining of LKB1 showing that LKB1 (green) was conditionally deleted in *Ctsk*⁺ periosteal cells (red) from *Ctsk-CKO; Rosa26-Ai9* mice, but not in *Ctsk-Ai9* cells of *Ctsk-Ctrl; Rosa26-Ai9* mice. Scale bar: 20 μ m. (I and J) Immunostaining showing *Ctsk-Cre*-positive cells (red) in the cortical bone display osteoblast markers OSX (green), COL1A1 (green), and OPN (green) in the tibiae of 4-week-old male *Ctsk-Ctrl; Rosa26-Ai9* and *Ctsk-CKO; Rosa26-Ai9* mice (white arrow). Scale bar: 20 μ m. (K) *Ctsk-Ai9* cells isolated from the cortical bone of tibiae from *Ctsk-Cre; Rosa26-Ai9* mice showed expression of osteoblastic markers OSX (green), COL1A1 (green), and OPN (green). Scale bar: 10 μ m. Data are represented as mean \pm SEM. * P < 0.05; ** P < 0.01; *** P < 0.001, unpaired Student's t test.




Figure 5. LKB1-deficient *Ctsk*⁺ cells display higher self-renewal and osteoblast differentiation ability. (A and B) Immunostaining of PCNA in *Ctsk*-Cre-expressing cells in *Ctsk*-CKO mice showed increased proliferation rate. Scale bar: 50 μ m. (C and D) Plate colony formation of *Ctsk*-Ai9 cells purified via flow cytometry from the cortical bone of *Ctsk*-Ctrl; *Rosa26*-Ai9 and *Ctsk*-CKO; *Rosa26*-Ai9 mice, showing an enhanced proliferation rate of cells from *Ctsk*-CKO; *Rosa26*-Ai9 mice. Scale bar: 10 μ m. (E and F) Confocal images showing that expanded *Ctsk*-Cre-positive cells (red) in the cortical bone of *Ctsk*-CKO; *Rosa26*-Ai9 tibiae displayed a higher frequency of CD44-positive cells (white arrows). Scale bar: 20 μ m. (G–I) Deletion of *Lkb1* in the periosteal cortical bone cells via Cre adenovirus (Adv-Cre) leads to increased osteoblast differentiation monitored by ALP staining. (G) Supernatant ALP activity relative to the cell number measured via Alamar blue (Ala.Blue) (H) and marker gene expression (I) after 7-day induction. (J–O) Transplantation of periosteum-derived cells from 4-week-old *Ctsk*-Ctrl; *Rosa26*-Ai9 and *Ctsk*-CKO; *Rosa26*-Ai9 mice to the nude mice subcutaneously. (K) Weight of bone organoids formed by *Ctsk*-Ctrl; *Rosa26*-Ai9 (3/5) and *Ctsk*-CKO; *Rosa26*-Ai9 (5/5) cells. (L and M) Representative images of H&E staining (L) and von Kossa staining (M) of the bone organoids. Scale bars: 500 μ m (left); 20 μ m (right). (N) Confocal imaging showing *Ctsk*-Ai9⁺ cells were involved in osteoid formation. Scale bar: 200 μ m. (O) Immunostaining of osteogenic marker, OSX (green), and OPN (green) showing osteogenic potential of transplanted *Ctsk*-Ai9 cells (white arrows). Scale bar: 20 μ m. Data are represented as mean \pm SEM. ** P < 0.01; *** P < 0.001, unpaired Student's t test.

Ctsk-CKO mice when compared with those in *Ctsk*-Ctrl mice (Figure 4, I and J). We also examined the non-long bones and found the distribution of *Ctsk*-positive cells in the periosteum of skull, spine, and sternum (Supplemental Figure 3, C and D). Moreover,

these periosteal *Ctsk*-Ai9 cells also expressed the preosteoblast marker COL1A1 (Supplemental Figure 3, C and D), indicating *Ctsk* as a marker of osteoblast progenitors that are responsible for bone formation in both long bones and non-long bones. *Ctsk*-Ai9

cells isolated from the cortical bone of *Ctsk-Ctrl*; *Rosa-Ai9* mice showed expression of osteoblastic markers *OSX*, *COL1A1*, and *OPN* (Figure 4K), suggesting an in vitro osteoblast differentiation ability of *Ctsk-Ai9* cells. Combined with the previous findings that *Ctsk*-positive cells represent a subset of perichondrial cells within the groove of Ranvier (28), we hypothesize that periosteum-derived *Ctsk*⁺ cells could act as periosteal mesenchymal stem cells, which can develop into osteoblasts.

Prx1⁺ cells have been reported as mesenchymal progenitors residing in both the periosteum of cortical bone and the BM (38). To determine whether *Lkb1*-deficient mesenchymal progenitors could be the origin of osteogenic tumors, we next generated *Prx1-Cre*; *Lkb1*^{fl/fl} (*Prx1*-CKO) mice. At the age of 20 weeks, *Prx1*-CKO mice showed abnormal nodules in the long bones, hip bones, and calvarial bones, but not in the vertebra bones (x-ray images; see Supplemental Figure 5A). H&E staining indicated that the osteoid tumor transgressed the cortex and BM cavity (Supplemental Figure 5B) and calcein-alizarin red double-labeled fluorescence showing a large mass of irregular and diffuse fluorochrome labeling, confirming a dramatic increase in new bone formation within the cortical bone of *Prx1*-CKO tibiae (Supplemental Figure 5C). This was consistent with the observation in *Ctsk*-CKO mice. Notably, SO staining indicated a profound disorganization of the growth plate in both femur and tibia of *Prx1*-CKO mice, which displayed an enchondroma-like phenotype (Supplemental Figure 5D). This phenotype had not been observed in *Ctsk*-CKO mice (Supplemental Figure 1, A and B). We found *Prx1*⁺ cells were expanded from the cortex to the marrow cavity in the periosteum and also expanded to form a mass of cartilage in the growth plate of *Prx1*-CKO mice (Supplemental Figure 5E). We then compared the distributions of *Ctsk*⁺ and *Prx1*⁺ cells using 4-week-old *Ctsk-Cre*; *Rosa26-mT/mG* and *Prx1-Cre*; *Rosa26-mT/mG* mice and found that, in the periosteum, both *Ctsk* and *Prx1* can label periosteum cells, but in the growth plate and articular cartilage, only *Prx1*⁺ cells but not *Ctsk*⁺ cells were seen (Supplemental Figure 5F). This indicated *Ctsk* and *Prx1* might represent 2 subsets of mesenchymal stem cell with different anatomic distributions and functions.

LKB1 inhibits self-renewal and osteoblast differentiation ability of Ctsk⁺ periosteal mesenchymal stem cells. To investigate the effects of *Lkb1* deficiency on *Ctsk*⁺ periosteal mesenchymal stem cells, we first assessed the effects of *Lkb1* deficiency on self-renewal ability of periosteum *Ctsk*⁺ cells. Proliferating cell nuclear antigen (PCNA) staining showed a rapid proliferation of *Ctsk*⁺ cells in the periosteum of *Ctsk*-CKO; *Rosa-Ai9* tibiae in vivo (Figure 5, A and B). Consistently, *Ctsk*-Ai9 cells were isolated via flow cytometry from the cortical bone of both *Ctsk-Ctrl*; *Rosa-Ai9* and *Ctsk*-CKO; *Rosa-Ai9* tibiae and the same number of sorted Ai9-positive cells were seeded. After 7-day culture, the cells from *Ctsk*-CKO; *Rosa-Ai9* mice showed enhanced proliferative ability compared with cells from *Ctsk-Ctrl*; *Rosa-Ai9* mice (Figure 5, C and D).

Based on the report that CD44⁺ cancer stem cells (CSCs) are responsible for self-renewal and tumor growth in heterogeneous cancer tissue (39) and that CD44 has also been identified as a self-renewal marker in osteosarcoma (40), we examined the expression of CD44 in *Ctsk-Ctrl* and *Ctsk*-CKO mice. Immunostaining of CD44 in the periosteum of *Ctsk-Ctrl*; *Rosa-Ai9* and *Ctsk*-CKO; *Rosa-Ai9* mice showed an increased population of CD44

in the inner surface of *Ctsk*⁺ periosteal cells (Figure 5, E and F). Reexpression of LKB1 via lentivirus in both *Ctsk-Ctrl*; *Rosa-Ai9* and *Ctsk*-CKO; *Rosa-Ai9* cells reduced the number of CD44-positive cells (Supplemental Figure 3, F and G). We reasoned that loss of *Lkb1* in periosteum-derived *Ctsk*⁺ cells caused the expansion of CD44-positive cells and drove osteogenic tumor formation.

We next examined the effects of *Lkb1* deficiency on osteoblast differentiation. We cultured periosteal cells from *Lkb1*^{fl/fl} mice and infected these cells with adenovirus expressing EGFP (Adv-EGFP) and Cre (Adv-Cre). Adv-Cre-infected cells showed increased ALP staining (Figure 5G) and higher supernatant ALP activity (Figure 5H) compared with Adv-EGFP-infected cells. Consistently, expression of osteoblast marker genes, including *Osx*, *Col1a1* and *Opn*, increased in Adv-Cre-infected cells (Figure 5I). In summary, these results support the idea that LKB1 deletion could increase the osteoblast differentiation ability of periosteal mesenchymal stem cells.

To further investigate whether *Lkb1*-deficient cells are sufficient to drive osteogenic tumor formation in normal mice, we transplanted the periosteum-derived cells from *Ctsk-Ctrl*; *Rosa-Ai9* and *Ctsk*-CKO; *Rosa-Ai9* mice to nude mice subcutaneously. Eight weeks after injection, H&E staining and confocal imaging of *Ctsk*-Ai9 cells demonstrated an osteoid region formed by *Ctsk*-Cre; *Rosa-Ai9* periosteal cells (Figure 5, L and N), which was consistent with the results showing that transplantation of *CTSK*⁺ periosteal stem cells under the kidney capsule of WT mice can de novo generate bone organoids (37). Moreover, periosteal cells from *Ctsk*-CKO; *Rosa-Ai9* mice developed larger bone organoids than cells from *Ctsk-Ctrl*; *Rosa-Ai9* mice (Figure 5, J-L). Cellular and nuclear atypia were observed in the osteoid matrix formed by *Ctsk*-CKO; *Rosa-Ai9* cells, but not that formed by control cells, showing features of neoplasia. von Kossa staining and expression of *OSX* and *OPN* in the transplanted *Ctsk*-Ai9⁺ cells demonstrated that *Ctsk*-Ai9⁺ cells have osteogenic potential (Figure 5, M and O). In summary, our data suggested that transplantation of the *Lkb1*-deficient *Ctsk*⁺ periosteal cells was sufficient to drive osteogenic tumor formation in normal mice.

Inhibition of mTORC1 signaling ameliorates tumor progression in Ctsk-CKO mice. To investigate the mechanism with which *Lkb1* deletion induces the osteogenic tumor from *Ctsk*-Cre-positive periosteal mesenchymal stem cells, we focused on the mTORC1 pathway, which is a critical target downstream of LKB1-dependent AMP kinases (AMPKs). Phosphorylation of mTORC1 catalytic substrate ribosomal protein S6 (S6) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) were increased in *Ctsk*-CKO mice (Figure 6A), indicating hyperactivation of mTORC1 signaling in *Ctsk*-CKO mice. We postulated that if LKB1 deletion indeed induces the osteogenic tumor-like phenotype via activation of the mTORC1 pathway, the deletion of *Raptor* (the core binding factor of mTORC1) in vivo should lead to amelioration of the osteogenic tumor-like phenotype in *Lkb1*^{fl/fl}; *Ctsk*-CKO mice. We constructed *Ctsk*-DKO mice (*Ctsk* Cre; *Lkb1*^{fl/fl}; *Raptor*^{fl/fl}) and found that delayed tumor progression in *Ctsk*-DKO mice was indicated by an extended median life span of 42.3 weeks compared with the life span of 23.9 weeks for *Lkb1*^{fl/fl}; *Ctsk*-CKO mice (Figure 6B). The disorganized architecture in the tibiae was partially rescued in *Ctsk*-DKO mice, as indicated by the results of x-ray and μ CT analyses (Figure 6C and Supplemental Figure 6A).




Figure 6. Inhibition of mTOR signaling delays tumor progression of Ctsk-CKO mice. (A) Immunostaining of phosphorylated mTORC1 catalytic substrates ribosomal protein S6 (p-S6) and p-4E-BP1 in sections of 20-week-old Ctsk-Ctrl and Ctsk-CKO tibiae. Scale bar: 20 μm . (B) Survival plots showing an extended median life span of 42.3 weeks for *Lkb1^{fl/fl}; Raptor^{fl/fl}; Ctsk-DKO* mice ($n = 10$) compared with 23.9 weeks for *Lkb1^{fl/fl}; Ctsk-CKO* mice ($n = 21$). $P = 0.0014$. (C) X-ray images of spines and tibiae from Ctsk-Ctrl, *Raptor^{fl/fl}; Ctsk-CKO*, *Lkb1^{fl/fl}; Ctsk-CKO*, and *Lkb1^{fl/fl}; Raptor^{fl/fl}; Ctsk-DKO* mice. (D and E) von Kossa staining and the periosteal MAR and BFR via calcein-alizarin red double labeling of tibiae from 5-week-old Ctsk-Ctrl, *Raptor^{fl/fl}; Ctsk-CKO*, *Lkb1^{fl/fl}; Ctsk-CKO* and *Lkb1^{fl/fl}; Raptor^{fl/fl}; Ctsk-DKO* mice. Scale bars: 50 μm (left); 20 μm (middle); 50 μm (right). (F) Immunostaining of CD44 expression in sections of 20-week-old Ctsk-Ctrl, *Lkb1^{fl/fl}; Ctsk-CKO*, and *Lkb1^{fl/fl}; Raptor^{fl/fl}; Ctsk-DKO* tibiae. Scale bar: 100 μm . (G and H) Representative x-ray images of spines and tibiae showing that treatment of Ctsk-Ctrl and Ctsk-CKO mice with rapamycin twice per week from 2 weeks old to 20 weeks old (G) or daily from 16 weeks old to 20 weeks old (H) delayed the tumor growth of Ctsk-CKO mice. Similar results were obtained from analyses of both male and female mice for each genotype. Data are represented as mean \pm SEM. $**P < 0.01$, unpaired Student's t test (B) and 2-way ANOVA (E).




Figure 7. Inhibition of mTORC1 inhibits human osteosarcoma cell growth in nude mice. (A) Western blot result of knockdown efficiency of LKB1 and hyperactivation of mTORC1 pathway in HOS-MNNG cells infected with shLKB1 lentivirus. (B–E) Nude mice were injected with shEGFP and shLKB1 HOS-MNNG cells and treated with 4 mg/kg rapamycin or vehicle control, respectively, daily since tumor establishment for 10 consecutive days. Tumor growth was monitored every 2 days (D), and tumor volume was measured after autopsy (C). Scale bar: 10 mm. Tumors were collected and sectioned for H&E staining. Ki67, LKB1, p-S6, and OSX expression were evaluated via immunohistochemical analysis (E). Scale bars: 20 μ m. * P < 0.05. (F) Schematic representation of key findings. Previous findings indicated that *Ptpn11* deletion in *Ctsk*⁺ cells from the perichondrial groove of Ranvier caused cartilage tumors via activating *Ihh* signaling. Our results suggest that loss of *Lkb1* in *Ctsk*-Cre-expressing mesenchymal progenitor in the periosteum caused osteogenic tumor-like phenotype by increasing mTORC1 activity. Data are represented as mean \pm SEM. * P < 0.05; ** P < 0.01; *** P < 0.001, 2-way ANOVA.

H&E staining showed decreased tumor size in *Ctsk*-DKO tibiae (Supplemental Figure 6B). As expected, both mineralization of the heterotopic bone within the cortical bone by von Kossa staining and increased periosteal MAR and BFR via double labeling were rescued in *Ctsk*-DKO mice when compared with *Ctsk*-CKO mice

(Figure 6, D and E). Moreover, we examined CD44-positive cells in the section of tibiae and found a robust decline in *Ctsk*-DKO mice (Figure 6F), indicating a correlation between the frequency of CD44-positive cells and tumor progression. These results suggested that the increased mTORC1 activity in *Ctsk*-CKO mice

could be pathogenic in tumor formation, which prompted us to test to determine whether an mTORC1 signaling inhibitor could slow tumor progression. Rapamycin, an mTORC1 inhibitor, was administered to both Ctsk-Ctrl and Ctsk-CKO mice via intraperitoneal injection twice per week starting at 2 weeks of age, when the cortical bone began to expand in Ctsk-CKO mice (data not shown). X-ray images and H&E staining indicated that rapamycin treatment significantly delayed tumor growth and improved the mobility of Ctsk-CKO mice at the age of 20 weeks (Figure 6G and Supplemental Figure 6C). To further examine the effects of rapamycin on advanced tumor, this drug was intraperitoneally injected daily from the age of 16 weeks. X-ray images and H&E staining indicated that daily rapamycin treatment for 4 weeks significantly relieved symptoms of osteogenic tumors in Ctsk-CKO mice (Figure 6H and Supplemental Figure 6D).

Inhibition of mTORC1 signaling prevents tumorigenesis in a xenograft model. To further investigate the clinical relevance of LKB1 loss with osteogenic sarcoma and the therapeutic effects of rapamycin treatment in human osteosarcoma, we used LKB1 shRNA (shLKB1) lentivirus to knock down LKB1 expression in the human osteosarcoma cell line HOS-MNNG cell, which has been reported to express high levels of LKB1 (24, 41). The knockdown efficiency of LKB1 and hyperactivation of the mTORC1 pathway in shLKB1 lentivirus-infected HOS-MNNG cells were confirmed via Western blot analysis (Figure 7A; see complete unedited blots in the supplemental material). We then injected HOS-MNNG cells that expressed either shEGFP or shLKB1 into nude mice. After tumor establishment, the mice were treated daily with either 4 mg/kg rapamycin or vehicle. As shown in Figure 7, B–D, tumor size was significantly enlarged in the shLKB1 group compared with the shEGFP control group. Histologically, shLKB1 tumors displayed an apparent nuclear variability, increased Ki67 expression, decreased OSX expression, and elevated S6 phosphorylation (Figure 7E). Rapamycin treatment was able to decrease the growth rate and tumor volume in both the shLKB1 group and the shEGFP control group (Figure 7, B–D). Rapamycin treatment decreased cell density, nuclear variability, Ki67 expression, OSX expression, and S6 phosphorylation. Immunohistochemical analysis confirmed the lowered expression of LKB1 in the shLKB1 group compared with that in the shEGFP control (Figure 7E). These data demonstrate that LKB1 knockdown promotes tumor formation of human osteosarcoma cells, while rapamycin inhibits tumor growth in established tumors using human osteosarcoma cell xenografts.

Discussion

Our results suggest that *Lkb1* deletion in Ctsk⁺ periosteal cells caused osteogenic tumor-like phenotype by increasing mTORC1 activity. Previous reports demonstrated that Ptpn11 deficiency in Ctsk⁺ cells induced metachondroma with decreased ERK activity and more production of the growth stimulators Ihh and Pthrp (28) (Figure 7F). To further understand why *Lkb1*-deficient mice developed osteogenic tumor, but not cartilage tumor, we examined expression of pErk in *Lkb1*-deficient Ctsk⁺ cells by immunostaining and Western blot and found that *Lkb1* deletion had no obvious effect on inhibition of Erk signaling (Supplemental Figure 7, A, B, and C; see complete unedited blots in the supplemental material) and production of *Ihh* and *Pthrp* (Supplemental Figure 7D). It

has been proven that hypoactivation of Erk signaling in Ctsk⁺ cells could induce cartilage tumor (28). However, *Lkb1* deficiency in Ctsk⁺ cells could not inhibit Erk/Ihh signaling and induce cartilage tumor. Our study expanded the definition of Ctsk⁺ as not only a progenitor of metachondroma, but also a source of osteosarcoma.

Consistent with the recent publication showing that Ctsk⁺ cells can function as periosteal stem cells to mediate intramembranous bone formation (37), our data also identified Ctsk⁺ periosteal cells as containing a stem cell population (CD31⁺CD45⁺Ter119⁺CD90.2⁺6C3⁺CD105⁺CD200⁺) (36). Deletion of *Lkb1* in Ctsk⁺ cells leading to osteosarcoma formation demonstrated that Ctsk⁺ cells cannot only serve as a physiologic precursor of periosteal osteoblasts, but also as a pathological precursor in osteogenic tumor. Regulation of the cell fate of this periosteal stem cell by deleting transcription factor OSX or tumor-suppressor LKB1 can lead to abnormal cortical architecture or even tumor formation, which shows the importance of understanding the cellular basis of skeletal pathology.

To clarify the role of *Lkb1* function in human osteosarcomagenesis, we first searched for genetic mutations in *Lkb1* in human osteosarcoma patients. However, genetic mutations in *Lkb1* have not yet been commonly found in human osteosarcoma, with the exception of one case report (c.937C>A) (42), which might be restricted by the low incidence rate of the disease and the low availability of samples for sequencing. In addition, allelic loss, LKB1 promoter hypermethylation, or reduced LKB1 expression is observed in a wide variety of sporadic cancers (43, 44). The study demonstrated that 41% of osteosarcoma patient loss of LKB1 protein expression was due to posttranslational regulation by SIRT1 deacetylase, but not due to genetic anomalies or loss of LKB1 mRNA levels (24), suggesting that decreases in LKB1 expression could also be important for osteosarcoma formation. Our study has proven that loss of *Lkb1* in Ctsk⁺ cells can lead to osteosarcoma formation in mice and that LKB1 deficiency in a human osteosarcoma cell line could accelerate tumor formation, suggesting that further examination of mutations in *Lkb1* and/or its upstream genes in human osteosarcoma is warranted.

As a known tumor suppressor, LKB1 is inactivated in a wide range of sporadic cancers, most of which show inactivation of AMPKs and a resulting hyperactivation of mTORC1 signaling (18, 19, 45). Another study used Sleeping Beauty transposon-based somatic forward genetic screening and reported that PI3K/AKT/mTOR signaling was involved in enhancing osteosarcomagenesis (46). Our results also suggest treatment of osteosarcoma by targeting LKB1/AMPK/mTORC1 signaling. The selective mTORC1 inhibitors sirolimus (rapamycin) (47, 48), ridaforolimus (49), and everolimus (50) have been studied in clinical trials for their osteosarcoma treatment potential, showing either complete or partial response in a portion of patients (1). Our mouse model can help with interpreting the mechanism of mTORC1 inhibitors for the treatment of osteosarcoma and adopting a targeted therapy through assessing the genetic mutation, epigenetic modification, and expression levels of the genes that are involved in the LKB1/mTORC1 signaling. The recent accelerated development of techniques for the rapid assessment of both the genetic and epigenetic statuses of tumor biopsies has birthed the concept of personalized medicine. Osteosarcoma presents a challenge for personalized medicine due to the absence of pathognomonic mutations combined with the rarity and

heterogeneity of the disease. This may account for the unsatisfactory results reported by recent trials for targeted therapies. Collaborative multicenter, international, deep-sequencing efforts to study this disease might lead to the discovery of new mutations in osteosarcoma patients in the future (51, 52).

It would be helpful to treat osteosarcoma using a combined therapeutic approach targeting different involved pathways to obtain synergistic effects. Angiogenesis is essential for cancer development and growth, and VEGF is a key mediator of angiogenesis in tumor (53). Previous evidence indicates that LKB1 alterations contribute to cancer progression by modulating VEGF production (54, 55). We examined the expression of VEGF in the tumor region of Ctsk-CKO mice and found increased VEGF production in Ctsk-CKO mice (Supplemental Figure 7, E and F; see complete unedited blots in the supplemental material). It might be rational to study combination therapy using rapamycin and anti-VEGF therapy to treat tumorigenesis in osteosarcoma patients with LKB1 loss.

The fact that deletion of Lkb1 in LysM⁺ cells does not lead to tumor mass formation within the cortical bone confirms that osteoclasts are not involved in the pathogenesis of Lkb1-related osteosarcomas. Actually, both Ctsk-CKO and LysM-CKO mice showed increased osteoclast formation (Figure 3, B and C, and Supplemental Figure 7, G and H), and the tumor mass in Ctsk-CKO mice contained a large number of osteoclasts and osteoclast precursors (Figure 3A). These data indicate that Lkb1 might play a role in osteoclastogenesis. Our previous study demonstrated that mTORC1 signaling plays a determinative role in osteoclast differentiation, as *Raptor* deficiency in osteoclasts resulted in increased bone mass with decreased bone resorption (56). It is possible that LKB1 deficiency in osteoclasts could also lead to mTORC1 activation. Further study is required to demonstrate the role of Lkb1 in osteoclastogenesis.

Methods

Animals. *Lkb1*^{f/f} mice were obtained as previously described (18, 57). *Raptor*^{f/f} mice bearing loxP sites flanking exon 6 of the *Raptor* gene, were from the Jackson Laboratory (catalog 013188). *Ctsk-Cre* mice were provided by S. Kato (University of Tokyo, Tokyo, Japan) (26). *LysM-Cre* mice were provided by Ira Tabas (Columbia University, New York, New York, USA) (33). *Rosa26-loxp-mTomato-stop-loxp-mGFP* (*Rosa26-mT/mG*) reporter mice and *Rosa26-loxp-stop-loxp-tdTomato* (*Rosa26-Ai9*) reporter mice were obtained as previously described (refs. 34, 35, respectively). All utilized mice were maintained on a C57BL/6 background, and sex-matched littermate controls were used for all analyses. Both male and female mice were analyzed. All animals were housed in specific pathogen-free conditions.

Radiographic assessment. For x-ray image analysis, mice were euthanized with CO₂, followed by removal of skin and internal organs. The skeletons were then fixed in 70% ethanol and analyzed via whole-body x-ray using an Eagle III Microspot X-ray Fluorescence (Exda Inc. USA) instrument and a Faxitron SR radiograph digital imaging system.

For μ CT analysis, tibiae and vertebrae isolated from age- and sex-matched mice were fixed in 70% ethanol and scanned using a SkyScan 1176 (Bruker Biospin) at a 20 μ m resolution for qualitative analysis or at a 10 μ m resolution for quantitative analysis. 3D images were reconstructed using a fixed threshold. The percentages of trabecular BV/TV

and cortical thickness (Ct.Th) were calculated for the cortical bone of diaphysis of the distal femur.

Histology analysis. For dynamic histomorphometry, 4-week-old mice received intraperitoneal injections of 20 mg/kg body weight calcein (MilliporeSigma, C0875) and 25 mg/kg body weight alizarin red (MilliporeSigma, A5533) with an interval of 4 days. The mice were euthanized with CO₂ at 3 days after alizarin red injection. Bone MAR and BFR were measured as previously described (58).

For undecalcified bone section, tibiae were fixed in 4% paraformaldehyde (PFA) for 48 hours at 4°C and dehydrated in a gradient of ethanol and acetone, followed by resin embedding. The tibiae were then cut into sections of 4 μ m thickness using a Leica RM2265 microtome. Calcium deposits in the bone tissue were visualized by von Kossa staining using 4% silver nitrate followed by 5% sodium thiosulfate and Van Gieson's counterstaining.

For paraffin sectioning, femurs and tibiae were fixed in 4% PFA for 48 hours at 4°C and decalcified in 15% EDTA. Specimens were dehydrated using a gradient ethanol and xylene and embedded with paraffin, and sections of 8 μ m thickness were cut using a Leica RM2235 microtome. Sections were dewaxed and rehydrated and then stained with H&E and SO. TRAP (MilliporeSigma, S387A-1KIT) staining was performed according to the manufacturer's instructions.

For frozen sectioning, freshly dissected tibiae were fixed in 4% PFA for 48 hours at 4°C, decalcified in 15% EDTA, and dehydrated in 30% sucrose for 48 hours. The tissue samples were then embedded with OCT (Tissue-Tek, 4583), and sections of 8 μ m thickness were cut using a Leica CM3050S cryostat.

Immunohistochemistry and immunofluorescence. For immunohistochemical staining, the paraffin sections were first dewaxed and rehydrated. Antigen retrieval was performed either with protease K at 37°C for 30 minutes or with citrate buffer solution (pH 6.0) at 95°C for 15 minutes according to the specific instructions for the primary antibody. After blocking and permeabilization with 3% BSA and 0.2% Triton-X 100 in PBS at room temperature for 45 minutes, the sections were incubated with primary antibodies, including rabbit anti-Ki67 (Leica Novocastra, catalog NCL-Ki67p, 1:500), rabbit anti-OSX (Santa Cruz Biotechnology Inc., catalog sc-133871, 1:400), rat anti-CD44 (Santa Cruz Biotechnology Inc., catalog sc-18849, 1:300), rabbit anti-p-S6 (Cell Signaling Technology, catalog 4858, 1:400), and rabbit anti-p-4E-BP1 (Cell Signaling Technology, catalog 2855, 1:400) overnight at 4°C. After washing, corresponding biotinylated secondary antibodies were incubated for 45 minutes at room temperature using either a VECTASTAIN ABC Kit (Vector Labs, PK-6100) or a Polink-2 Plus Polymer HRP Detection System (ZSGB-BIO, PV9004). DAB (Vector Labs, SK-4100) was used as substrate. The nuclei were counterstained using hematoxylin, and sections were dehydrated and mounted using neutral balsam.

For immunofluorescence staining, frozen sections were air-dried and rehydrated with PBS and then blocked and permeabilized with 3% BSA and 0.2% Triton-X 100 in PBS at room temperature for 45 minutes. Sections were probed with primary antibodies against rabbit anti-LKB1 (Santa Cruz Biotechnology Inc., catalog sc-28788, 1:300), mouse anti-PCNA (Santa Cruz Biotechnology Inc., catalog sc-56, 1:400), goat anti-OPN (R&D, catalog AF808, 1:500), rabbit anti-OSX (Santa Cruz Biotechnology Inc., catalog sc-133871, 1:400), rat anti-CD44 (Santa Cruz Biotechnology Inc., catalog sc-18849, 1:300), rabbit anti-perilipin A/B (MilliporeSigma, catalog P1873, 1:1000),

rabbit anti-laminin A/B (MilliporeSigma, catalog L9393, 1:1000), rat anti-CD31 (Abcam, catalog ab7388, 1:500), and rabbit anti-COL1A1 (Rockland, catalog RK-600-401-103, 1:200) overnight at 4°C. Fluorescence-labeling secondary antibodies including donkey anti-rabbit Alexa Fluor488 (Molecular Probes, catalog A21206, 1:1000), donkey anti-goat Alexa Fluor 488 (Molecular Probes, catalog A11055, 1:1000), donkey anti-rat Alexa Fluor488 (Molecular Probes, catalog A21208, 1:1000), and donkey anti-mouse Alexa Fluor488 (Molecular Probes, catalog A21202, 1:1000) were incubated for 1 hour at room temperature after washing. Nuclei were counterstained with DAPI (MilliporeSigma, D9542). Sections were mounted using fluorescence mounting medium (Dako, S3023).

Total RNA preparation and quantitative RT-PCR analysis. Total RNA was extracted from cortical bone ground in liquid nitrogen using TRIzol (MilliporeSigma, T9424), following the instructions of the manufacture. An aliquot of 500 ng total RNA was reverse-transcribed to cDNA using TaKaRa PrimeScript Reverse Transcriptase (TaKaRa, RR037A). Quantitative PCR (qPCR) was performed using a SYBR green mixture (Takara) and a Bio-Rad CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories). Primers used for specific transcripts are listed in Supplemental Table 1.

Isolation and culture of cortical bone cells. Femurs and tibiae were thoroughly cleaned to remove all soft tissues, and the epiphysis and metaphysis were then removed. The BM was flushed out with D-PBS using a 0.45 mm syringe needle. Diaphysis of femurs and tibiae were preserved in ice-cold PBS and then digested with 1 mg/ml collagenase (MilliporeSigma, C0130), 2 mg/ml 100 mg dispase II (MilliporeSigma, D4693), and 2% penicillin/streptomycin in minimum essential medium α (α -MEM; Corning, 10-022-CVR) at 37°C for 30 minutes. The cell suspension was passed through a 70 μ m nylon mesh (BD Falcon, BD Biosciences, 352350) and plated in 1 well of a 6-well plate in growth medium (α -MEM containing 10% FBS; Ausbian, VS500T) and 1% penicillin/streptomycin (Gibco, Thermo Fisher Scientific, 10378-016). Cells were replated into a 6 cm dish when reaching 80%–90% confluency.

Flow cytometry. To sort Ctsk-Ai9 cells, primary isolated cortical bone cells were cultured for 7 days and then digested to a single cell suspension. Cell sorting was performed with an Arial II Cell Sorter (BD Biosciences). Adhesive cells and debris were excluded via forward scatter (FSC) and side scatter (SSC) profiles. Sorted cells were plated at a density of 30,000 cells per cm² in growth medium.

For the analysis of periosteum-derived Ctsk-Ai9 cells from cortical bone of Ctsk-Ctrl and Ctsk-CKO mice, equal numbers of cells were added into each individual tube for different antibodies before immunostaining, following the method previously described (36, 37, 59). RBCs were first removed by RBC lysis buffer (Beyotime, C3702). Then the cells were stained with eFluor 450 anti-CD31 (eBioscience, 48-0311-80), PerCP/Cy5.5 anti-CD45 (BioLegend, 103132), APC/Cy7 anti-mouse TER-119 (BioLegend, 116223), Biotin anti-mouse CD51 (BioLegend, 104103), Brilliant Violet 510 Streptavidin (BioLegend, 405233), FITC anti-mouse 6C3/Ly-51 (BioLegend, 108305), Brilliant Violet 605 anti-mouse CD90.2 (BioLegend, 140317), PE/Cy7 anti-mouse CD105 (BioLegend, 120409), APC anti-mouse CD200 (BioLegend, 123809), APC anti-human/mouse CD49f (BioLegend, 313615), APC anti-mouse CD146 (BioLegend, 134711), APC anti-mouse CD24 (BioLegend, 138505), biotin anti-mouse PDGFA/CD140a (Invitrogen, 13-1401-82), (BioLegend), biotin anti-mouse PDGFB/CD140b (BioLegend, 13239939), biotin anti-mouse LepR (R&D, BAF497), APC

streptavidin (BioLegend, 405243), APC anti-CD44 (BD Biosciences — Pharmingen, 559250), APC anti-Sca1 (eBioscience, 17-5981-81), rabbit anti-LKB1 (Santa Cruz Biotechnology Inc., sc-28788, 1:300), and anti-rabbit Alexa Fluor 488 (Molecular Probes, A21206, 1:1000), respectively. For internal antigen staining, cells were fixed in PFA and permeabilized in permeabilization buffer (Invitrogen, 00-8333-56) after surface marker staining. After washing with PBS, flow cytometric analysis was conducted and analyzed using Beckman CytoFlex FCM.

In vitro differentiation assays. For osteoblast differentiation, primary *Lkb1^{fl/fl}* cortical bone cells that had been infected with either GFP-adenovirus or Cre-adenovirus or Ctsk-Ai9 cortical bone cells that were sorted by flow cytometry were plated in a 96-well plate at 2×10^4 cells per well. Cells were cultured in osteoblast induction medium (α -MEM containing 10% FBS, 5 mM β -glycerophosphate [MilliporeSigma, G9422], 50 μ g/ml L-ascorbic acid [MilliporeSigma, A5960], and 1% penicillin/streptomycin [Gibco, Thermo Fisher Scientific, 15140-122]). The medium was changed every 3 days. After 7 days of induction, cells were fixed with 10% neutral buffered formalin (MilliporeSigma, HT501320) and stained with the BCIP/NBT ALP Staining Kit (Beyotime, C3206) following the manufacturer's instructions. For quantitative analysis of cell growth and ALP activity, cells cultured for 4, 7, and 10 days were incubated with alamarBlue (Thermo Fisher Scientific, 88951) for 2 hours at 37°C and read using a multi-mode plate reader (Envision, PerkinElmer) with excitation at 540 nm and emission detection at 590 nm. After aspirating alamarBlue reaction mixture, cells were incubated with ALP substrate solution containing 6.5 mM Na₂CO₃, 18.5 mM NaHCO₃, 2 mM MgCl₂, and 1 mg/ml phosphatase substrate (MilliporeSigma, S0942) for 20 minutes and read with Envision using the absorption detection mode at 405 nm.

For chondrocyte differentiation, a micromass culture method was used to determine the chondrocyte differentiation ability. Sorted Ctsk-Ai9 cortical bone cells (5×10^6 cells/ml) were seeded as a 10 μ l micromass drop in a culture well in a 24-well plate and incubated at 5% CO₂ and 37°C for 2 hours to allow cell attachment. Then, 1 ml of chondrocyte induction medium (α -MEM containing 10% FBS, 1% ITS [Cyagen, ITSS-10201-10], 10 ng/ml TGF- β 3 [Peprotech, 100-36E], 100 nM dexamethasone [MilliporeSigma, D1756], 1 mM sodium pyruvate [MilliporeSigma, 25-000-CIR], 40 μ g/ml proline [MilliporeSigma, P5607], 50 μ g/ml L-ascorbic acid 2-phosphate [MilliporeSigma, A8960], and 1% penicillin/streptomycin) was added and incubated for 4 days. The micromass was acidified with 0.1 N HCl and stained with 1% alcian blue (MilliporeSigma, A5268).

For adipocyte differentiation, 6×10^4 sorted Ctsk-Ai9 cortical bone cells were plated in a well in a 96-well plate and cultured with adipocyte induction medium (α -MEM with 10% FBS, 50 mM dexamethasone [MilliporeSigma, D1756], 100 nM rosiglitazone [MilliporeSigma, R2408], 500 nM 3-isobutyl-1-methylxanthine (IBMX) [MilliporeSigma, I5879], 10 mg/ml insulin [MilliporeSigma, 91077c], and 1% penicillin/streptomycin) for 1 day, followed by adipocyte maintenance medium (α -MEM with 10% FBS, 10 mg/ml insulin, and 1% penicillin/streptomycin) for 3 days. Cells were then fixed and stained with 2 mg/ml of either oil red O (MilliporeSigma, O1391) or Bodipy FL (Invitrogen).

For osteoclast differentiation, 3×10^6 cells/ml nonadherent BM cells isolated from the femurs and tibiae of mice were seeded in BMM induction medium (α -MEM with 10% FBS, 10 ng/ml M-CSF, and 1% penicillin/streptomycin) in a 96-well plate for 3 days, then in osteoclast induction medium (α -MEM with 10% FBS, 20 ng/ml M-CSF,

150 ng/ml RANKL, and 1% penicillin/streptomycin) for 4 days. The cultured supernatant was harvested for detection of TRAP activity following the method previously described (56). TRAP staining of the cell was performed using a TRAP staining kit (MilliporeSigma, S387A-1KIT) following manufacturer's instructions.

Rapamycin treatment. Rapamycin (Selleck, S1039) treatment was conducted in male and female littermates of *Ctsk-Ctrl* and *Ctsk-CKO* mice. Rapamycin was dissolved in 2% DMSO and 5% TWEEN-80 in water following the manufacturer's instructions. Rapamycin and its solvent control were given intraperitoneally at a dose of either 4 mg/kg twice per week beginning at 2 weeks or at 4 mg/kg daily beginning at 16 weeks to an age of 20 weeks. X-ray images of the whole skeleton and H&E staining of the tibiae were obtained to estimate the overall effect on tumor growth.

Xenograft tumors and drug therapy in nude mice. Four-week-old female nude mice were subcutaneously injected (close to the groin) with 1×10^6 HOS-MNNG cells or 1×10^7 total periosteum-derived cells isolated from *Ctsk-Ctrl*; *Rosa-Ai9* and *Ctsk-CKO*; *Rosa-Ai9* mice in 0.1 ml PBS. For drug therapy, as soon as the tumors reached 100 mm³, nude mice were randomly assigned to either vehicle or rapamycin (4 mg/kg) treatment groups and intraperitoneally injected daily. Tumor volume was measured using digital calipers every 2 days. Tumor volume was calculated by the formula: volume = length \times (width)²/2. Data points were expressed as an average tumor volume.

Statistics. Data were generated from independently obtained data sets and were expressed as mean \pm SEM. Statistical significance was determined using 2-tailed *t* tests or 2-way ANOVA. *P* values below 0.05 were considered to indicate statistically significant differences. GraphPad Prism 6 was used for all statistical analyses.

Study approval. Animal experiments were approved and conducted in full accordance with protocols that were approved by the Institutional Animal Care and Research Advisory Committee of Shanghai Institute of Biochemistry and Cell Biology.

Author contributions

WZ and YH designed experiments and interpreted results. YH carried out most of the experimental work with the help of HJ, WX, and QD. HF, JS, and YY helped with animal experiments. XL, Z Wang, AH, QB, and TK helped with histology analysis. Z Wei helped with μ CT analysis. YH and WZ analyzed the data and wrote the manuscript. All authors discussed and commented on the manuscript.

Acknowledgments

We thank S. Kato for *Ctsk-Cre* mice, H. Ji for *Lkb1^{fl/fl}* mice, M. Tong for *Raptor^{fl/fl}* mice, and N. Qian for helping with x-ray image analysis; We thank Matthew B. Greenblatt for critical reading and helpful discussion. We also thank the cell biology core facility and the animal core facility of Shanghai Institute of Biochemistry and Cell Biology for assistance. This work was supported in part by grants from the Strategic Priority Research Program of the Chinese Academy of Sciences (grant XDB19000000), the National Natural Science Foundation of China (NSFC) (grants 81672119, 81672769), and the 973 Program from the Chinese Ministry of Science and Technology (MOST) (grants 2015CB964503) and WZ is a scholar of the National Science Fund for Distinguished Young Scholars (NSFC) (grant 81725010).

Address correspondence to: Weiguo Zou, State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Sciences, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 YueYang Road, Shanghai 200031, China. Phone: 86.21.54921320; Email: zouwg94@sibcb.ac.cn. Or to Tiebang Kang, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China, 510060. Phone: 86.20.87343183; E-mail: kangtb@sysucc.org.cn.

- Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. *Nat Rev Cancer*. 2014;14(11):722-735.
- Coindre JM. [New WHO classification of tumours of soft tissue and bone]. *Ann Pathol*. 2012;32(5 Suppl):S115-S116.
- Uluçkan Ö, Segaliny A, Botter S, Santiago JM, Mutsaers AJ. Preclinical mouse models of osteosarcoma. *Bonekey Rep*. 2015;4:670.
- Abarrategi A, et al. Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies. *Stem Cells Int*. 2016;2016:3631764.
- Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. *Carcinogenesis*. 2009;30(10):1789-1795.
- Wunder JS, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. *J Clin Oncol*. 2005;23(7):1483-1490.
- Lengner CJ, et al. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. *J Cell Biol*. 2006;172(6):909-921.
- Berman SD, et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. *Proc Natl Acad Sci U S A*. 2008;105(33):11851-11856.
- Mutsaers AJ, et al. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. *Bone*. 2013;55(1):166-178.
- Walkley CR, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. *Genes Dev*. 2008;22(12):1662-1676.
- Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. Rb regulates fate choice and lineage commitment in vivo. *Nature*. 2010;466(7310):1110-1114.
- Del Mare S, et al. WWOX and p53 dysregulation synergize to drive the development of osteosarcoma. *Cancer Res*. 2016;76(20):6107-6117.
- Tao J, et al. Notch activation as a driver of osteogenic sarcoma. *Cancer Cell*. 2014;26(3):390-401.
- Osasan S, Zhang M, Shen F, Paul PJ, Persad S, Sergi C. Osteogenic sarcoma: a 21st century review. *Anticancer Res*. 2016;36(9):4391-4398.
- Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? *Bone*. 2014;62:56-63.
- Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. *Acta Physiol (Oxf)*. 2009;196(1):65-80.
- Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer*. 2009;9(8):563-575.
- Ji H, et al. LKB1 modulates lung cancer differentiation and metastasis. *Nature*. 2007;448(7155):807-810.
- Liu W, et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. *Cancer Cell*. 2012;21(6):751-764.
- Kottakis F, et al. LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. *Nature*. 2016;539(7629):390-395.
- Momicilovic M, Shackelford DB. Targeting LKB1 in cancer - exposing and exploiting vulnerabilities. *Br J Cancer*. 2015;113(4):574-584.
- Robinson J, Nye E, Stamp G, Silver A. Osteogenic tumours in Lkb1-deficient mice. *Exp Mol Pathol*. 2008;85(3):223-226.
- Rossi DJ, et al. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. *Proc Natl Acad Sci U S A*. 2002;99(19):12327-12332.
- Presneau N, Duhamel LA, Ye H, Tirabosco R, Flanagan AM, Eskandarpour M. Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas. *Br J Cancer*. 2017;117(3):398-408.

25. Littlewood-Evans A, et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. *Bone*. 1997;20(2):81–86.
26. Nakamura T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. *Cell*. 2007;130(5):811–823.
27. Elefteriou F, Yang X. Genetic mouse models for bone studies—strengths and limitations. *Bone*. 2011;49(6):1242–1254.
28. Yang W, et al. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. *Nature*. 2013;499(7459):491–495.
29. Lai LP, Lilley BN, Sanes JR, McMahon AP. Lkb1/Stk11 regulation of mTOR signaling controls the transition of chondrocyte fates and suppresses skeletal tumor formation. *Proc Natl Acad Sci U S A*. 2013;110(48):19450–19455.
30. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. *Cancer Res*. 1993;53(1):16–18.
31. Mendoza S, David H, Gaylord GM, Miller CW. Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. *Cancer Genet Cytogenet*. 2005;158(2):142–147.
32. Kansara M, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. *J Clin Invest*. 2009;119(4):837–851.
33. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. *Transgenic Res*. 1999;8(4):265–277.
34. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. *Genesis*. 2007;45(9):593–605.
35. Madisen L, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat Neurosci*. 2010;13(1):133–140.
36. Chan CK, et al. Identification and specification of the mouse skeletal stem cell. *Cell*. 2015;160(1–2):285–298.
37. Debnath S, et al. Discovery of a periosteal stem cell mediating intramembranous bone formation. *Nature*. 2018;562(7725):133–139.
38. Wang C, et al. NOTCH signaling in skeletal progenitors is critical for fracture repair. *J Clin Invest*. 2016;126(4):1471–1481.
39. Prince ME, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. *Proc Natl Acad Sci U S A*. 2007;104(3):973–978.
40. Gibbs CP, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. *Neoplasia*. 2005;7(11):967–976.
41. Takeda S, et al. LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. *Anticancer Res*. 2007;27(2):761–768.
42. Reimann E, Köks S, Ho XD, Maasalu K, Mårtensson A. Whole exome sequencing of a single osteosarcoma case—integrative analysis with whole transcriptome RNA-seq data. *Hum Genomics*. 2014;8:20.
43. Korsse SE, Peppelenbosch MP, van Veelen W. Targeting LKB1 signaling in cancer. *Biochim Biophys Acta*. 2013;1835(2):194–210.
44. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. *Oncogene*. 2007;26(57):7825–7832.
45. Hemminki A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature*. 1998;391(6663):184–187.
46. Moriarty BS, et al. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. *Nat Genet*. 2015;47(6):615–624.
47. Schuetz SM, Baker LH, Maki RG. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. *J Clin Oncol*. 2006;24(suppl 18):9503. http://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.9503. Published online December 12, 2016. Accessed February 15, 2019.
48. Martin-Broto J, et al. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). *Ann Oncol*. 2017;28(12):2994–2999.
49. Chawla SP, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. *J Clin Oncol*. 2012;30(1):78–84.
50. Grignani G, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. *Lancet Oncol*. 2015;16(1):98–107.
51. Morrow JJ, et al. mTOR inhibition mitigates enhanced mRNA translation associated with the metastatic phenotype of osteosarcoma cells in vivo. *Clin Cancer Res*. 2016;22(24):6129–6141.
52. Pignochino Y, et al. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. *Clin Cancer Res*. 2013;19(8):2117–2131.
53. Wu JB, Tang YL, Liang XH. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy. *Onco Targets Ther*. 2018;11:6901–6909.
54. Ylikorkala A, et al. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. *Science*. 2001;293(5533):1323–1326.
55. Yalniz Z, Tigli H, Tigli H, Sanli O, Dalay N, Buyru N. Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma. *Tumour Biol*. 2014;35(12):12361–12368.
56. Dai Q, et al. Inactivation of regulatory-associated protein of mTOR (Raptor)/mammalian target of rapamycin complex 1 (mTORC1) signaling in osteoclasts increases bone mass by inhibiting osteoclast differentiation in mice. *J Biol Chem*. 2017;292(1):196–204.
57. Bardeesy N, et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. *Nature*. 2002;419(6903):162–167.
58. Dempster DW, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res*. 2013;28(1):2–17.
59. Gulati GS, et al. Isolation and functional assessment of mouse skeletal stem cell lineage. *Nat Protoc*. 2018;13(6):1294–1309.